03/20/2026
Cannabis Compounds CBD and CBG May Help Treat Fatty Liver Disease Affecting One-Third of Adults Worldwide
Recent research indicates that certain non-psychoactive compounds from the cannabis plant show promising potential in addressing fatty liver disease, also known as metabolic dysfunction-associated steatotic liver disease (MASLD).
This condition, affecting a large portion of adults worldwide, involves excessive fat accumulation in the liver, often linked to obesity, insulin resistance, and metabolic issues, with limited approved treatments beyond lifestyle changes.
The key compounds investigated are cannabidiol (CBD) and cannabigerol (CBG), both lacking the intoxicating effects of THC.
In preclinical experiments using obese mice fed high-fat diets to induce liver fat buildup, treatment with these compounds over four weeks significantly reduced hepatic triglycerides (liver fat), normalized blood lipid profiles, and improved glycemic control by enhancing insulin sensitivity and glucose clearance.
CBG demonstrated particularly strong effects, more robustly lowering body fat mass, "bad" LDL cholesterol, and overall metabolic markers compared to CBD. The beneficial outcomes appear to stem from mechanisms independent of classical cannabinoid receptors.
Instead, the compounds promote metabolic remodeling in the liver, boosting phosphocreatine-based energy buffering as a backup system and restoring lysosomal function for better cellular cleanup and waste removal.
This dual action helps the liver better handle lipids, reduce harmful accumulation, and combat inflammation and oxidative stress tied to disease progression.
While these findings highlight CBD and CBG as exciting, plant-derived candidates for future therapies, the evidence remains preclinical—primarily from animal models—and human clinical trials are still needed to confirm safety, optimal dosing, efficacy, and long-term impacts in people.
————————————————————
A Potential New Plant Based Treatment Path
Although the results are promising, the researchers emphasize that further studies are needed to determine how these findings may translate to human treatments. Additional research will help clarify whether these compounds could eventually be developed into therapies.
Still, the study highlights an emerging direction in metabolic disease research. By targeting how cells store energy and clear waste, plant derived compounds such as CBD and CBG may open new possibilities for treating fatty liver disease and related metabolic disorders.
Links:
https://lnkd.in/gpD2cnva
https://lnkd.in/gt6sD9Hj
https://lnkd.in/g7WN3anX
Source: Hebrew University of Jerusalem, British Journal of Pharmacology